INT178130

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 6.18
Pain Relevance 1.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (EDNRB) signal transducer activity (EDNRB)
Anatomy Link Frequency
plasma 1
smooth muscle 1
smooth muscle cells 1
lungs 1
parenchyma 1
EDNRB (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 337 99.46 Very High Very High Very High
fibrosis 2 91.48 High High
cytokine 12 89.72 High High
agonist 27 84.88 Quite High
qutenza 14 83.12 Quite High
Calcitonin gene-related peptide 39 80.64 Quite High
Inflammation 16 78.32 Quite High
Kinase C 11 77.44 Quite High
Neurotransmitter 7 75.52 Quite High
Potency 3 66.56 Quite High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 164 99.92 Very High Very High Very High
Cancer 226 98.92 Very High Very High Very High
Apoptosis 64 97.76 Very High Very High Very High
Natriuresis 14 96.68 Very High Very High Very High
Metastasis 45 96.40 Very High Very High Very High
Pulmonary Hypertension 491 95.88 Very High Very High Very High
Prostate Cancer 114 94.84 High High
Stress 21 93.56 High High
Hypoxia 36 92.84 High High
Fibrosis 2 91.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was reduced by BQ788 (1 µM; Fig. 6E) and was prevented by presence of either ET-1 (16 nM) or of both BQ788 (1 µM) and BQ123 (1 µM)[2] indicating selective binding to ETA- and ETB-receptors.
ETB Binding (binding) of in smooth muscle
1) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.43
The peptide is synthesized by endothelial cells and either binds to the ETA receptor on smooth muscle cells to mediate vasoconstriction or binds to the ETB receptor on endothelial cells to mediate vasodilation via the autocrine release of NO, prostacyclin and by increasing removal of endothelin from the circulation.
ETB Binding (binds) of in smooth muscle cells associated with increased venous pressure under development
2) Confidence 0.35 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 1.40 Pain Relevance 0.03
Endothelin antagonists are often identified as being “selective” (usually for the ETA type receptor) or “nonselective” (binding to either ETA or ETB receptors with similar affinity).
ETB Binding (binding) of associated with antagonist
3) Confidence 0.35 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994033 Disease Relevance 0.47 Pain Relevance 0.17
The ETA receptor binds ET-1 and ET-2 with greater affinity than it does ET-3, whereas the ETB receptor binds all three isoforms with equal affinity (Simonson and Dunn 1990).
ETB receptor Binding (binds) of
4) Confidence 0.27 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.49 Pain Relevance 0
Endothelins exert their effects by binding to two distinct cell surface ET receptors, ETA and ETB.
ETB Binding (binding) of
5) Confidence 0.27 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.28 Pain Relevance 0.08
The ETB receptor (ETBR) binds the three peptide isotypes with equal affinity.
ETB receptor Binding (binds) of
6) Confidence 0.27 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.27 Pain Relevance 0.08
The ETB receptor (ETBR) binds the three peptide isotypes with equal affinity.
ETBR Binding (binds) of
7) Confidence 0.27 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.27 Pain Relevance 0.08
As discussed earlier, selectivity of an ERA is usually determined by its ability to bind ETA and ETB in a standard in vitro assay.
ETB Binding (bind) of associated with antagonist
8) Confidence 0.21 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.05 Pain Relevance 0.23
Clearance of ET-1 occurs primarily via binding to ETB, particularly in the vascular beds of the lungs and kidney.
ETB Binding (binding) of in kidney
9) Confidence 0.21 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.09 Pain Relevance 0.08
Bosentan is an orally available, nonpeptide endothelin receptor antagonist that blocks both ET-A and ET-B receptors.
ET-B Binding (receptors) of associated with antagonist
10) Confidence 0.12 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 0.85 Pain Relevance 0.29
ET-B binding in lung, liver, and kidney parenchyma is believed to be one mechanism of clearance of endothelin.
ET-B Binding (binding) of in parenchyma
11) Confidence 0.10 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 0.88 Pain Relevance 0.21
Clearance of ET-1 occurs primarily via binding to ETB, particularly in the vascular beds of the lungs and kidney.
ETB Binding (binding) of in lungs
12) Confidence 0.07 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.09 Pain Relevance 0.08
The endothelins bind to two receptors, endothelin-A and endothelin-B, and play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis.67 Patients with metastatic prostate cancer have elevated levels of plasma endothelin-1 compared with patients with organ-confined cancer.
endothelin-B Binding (bind) of in plasma associated with cancer, prostate cancer, apoptosis and metastasis
13) Confidence 0.02 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 1.03 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox